



Lexi
Real TAKHZYRO patient

D.J.
Partner and caregiver

REIMAGINE LIFE WITH HAE

A resource for caregivers

WHAT IS TAKHZYRO?

TAKHZYRO is a prescription medicine used to prevent attacks of hereditary angioedema (HAE) in people 12 years of age and older.

It is not known if TAKHZYRO is safe and effective in children under 12 years of age.

IMPORTANT SAFETY INFORMATION

TAKHZYRO may cause serious side effects, including allergic reactions. Call your healthcare provider or get emergency help right away if you have any of the following symptoms:

- wheezing
- chest tightness
- faintness
- hives
- difficulty breathing
- fast heartbeat
- rash

Please see additional Important Safety Information throughout and full [Prescribing Information](#), including information for patients.

TAKHZYRO[®]
(lanadelumab-flyo) injection

REIMAGINE THE POSSIBILITIES WITH TAKHZYRO

A new chapter begins

As a caregiver, you are on the front lines of HAE. It's a role filled with highs and lows. Whether you are a primary advocate or simply providing assistance, the support you give is invaluable.

As your loved one starts a new journey with TAKHZYRO, you may have questions. Learning about their treatment can be empowering and help you provide the support they need.



**1 SUBCUTANEOUS SELF-INJECTION
EVERY 2 WEEKS**



**FEWER ATTACKS OR ZERO ATTACKS
IN A CLINICAL STUDY**



PLASMA FREE

TAKHZYRO is made using cells in a lab—so it does not depend on human plasma donations

In a 26-week clinical trial of 125 people with HAE 12 years of age and older, TAKHZYRO significantly reduced the number of monthly attacks, compared with placebo. People taking TAKHZYRO also had fewer moderate or severe attacks and fewer attacks requiring acute treatment, compared with placebo. And according to a supportive analysis, there were people taking TAKHZYRO who had zero attacks during the entire trial.

The recommended dose is 300 mg once every 2 weeks for people starting on TAKHZYRO. If a patient has zero attacks for more than 6 months, their healthcare provider may consider prescribing TAKHZYRO 300 mg once every 4 weeks.

IMPORTANT SAFETY INFORMATION (cont'd)

The most common side effects seen with TAKHZYRO were injection site reactions (pain, redness, and bruising), upper respiratory infection, and headache.

These are not all the possible side effects of TAKHZYRO. For more information, ask your healthcare provider or pharmacist. You may report side effects to the FDA at 1-800-FDA-1088.

Please see additional Important Safety Information throughout and full [Prescribing Information](#), including information for patients.

TAKHZYRO[®]
(lanadelumab-flyo) injection

STAYING ON TRACK WITH YOUR SUPPORT

Establish a treatment routine with your loved one

TAKHZYRO is eliminated as the body processes it, so it needs to be taken consistently. As a caregiver, you can play an important role in reminding your loved one **to take TAKHZYRO exactly as prescribed**. This means taking it as directed by their healthcare provider and **not missing or skipping doses**.



“*Don't lose hope. There is support out there. There is help out there. And there is a community of people who have gone through the same exact situation that you are in.*”

—**Juan**
Caregiver

TAKHZYRO TIP:

Use the **TAKHZYRO Journey Journal** that came in the Welcome Kit to keep track of doses, attacks, and progress on treatment goals.

IMPORTANT SAFETY INFORMATION (cont'd)

TAKHZYRO has not been studied in pregnant or breastfeeding women. Talk to your healthcare provider about the risk of taking TAKHZYRO if you are pregnant, plan to be pregnant, are breastfeeding, or plan to breastfeed.

Please see additional Important Safety Information throughout and full **Prescribing Information**, including information for patients.

TAKHZYRO[®]
(lanadelumab-flyo) injection



Al
Husband and caregiver

Marie
Real TAKHZYRO patient

Hear from other caregivers in "TAKHZYRO Talk: What's the Best Thing About Being a Caregiver?" at [TAKHZYRO.com](https://www.takhyro.com).

Please see Important Safety Information throughout and full **Prescribing Information**, including information for patients.

TAKHZYRO[®]
(lanadelumab-flyo) injection

TREATMENT THAT CONTINUES TO WORK AS THEY TAKE IT


Help your loved one get the most out of treatment

As someone keeps taking TAKHZYRO, the amount of medicine in their body will become constant after about 6 doses.

While they take TAKHZYRO, you may notice that the attacks they do have are less severe or that they use acute treatment less often. These are all signs that their treatment is working.

Like many medicines, TAKHZYRO needs to be taken regularly. Remember, it could take a few months for their treatment to reach its full potential.

Some ways to remember



Sign up for the TAKHZYRO Text Reminder Program:

Get dosing reminders delivered straight to your mobile phone. Visit [TAKHZYRO.com](https://www.takhzyro.com) or text SIGNUP to 36395 to get started*



Share a calendar: If you both have access to a calendar (digital or print), put a note on it for dosing days



Save the date: Help get into a routine by choosing a dosing day that will be easy to remember—for example, "TAKHZYRO Tuesday"

*Message and data rates may apply. Average of 3 messages per month. Text HELP to 36395 for more information, or text STOP to 36395 to end text reminders. View our Terms & Conditions at [engagedrx.com/tak](https://www.engagedrx.com/tak).

IMPORTANT SAFETY INFORMATION

TAKHZYRO may cause serious side effects, including allergic reactions. Call your healthcare provider or get emergency help right away if you have any of the following symptoms:

- wheezing
- chest tightness
- faintness
- hives
- difficulty breathing
- fast heartbeat
- rash

Please see additional Important Safety Information throughout and full [Prescribing Information](#), including information for patients.

TAKHZYRO[®]
(lanadelumab-flyo) injection

OnePath® IS HERE TO HELP

OnePath is a free product support program for eligible patients who have been prescribed a Takeda product. If you have any questions or need assistance, do not hesitate to reach out. OnePath is available at **1-866-888-0660**, Monday through Friday, 8:30 AM to 8:00 PM ET.

Here are just a few ways that OnePath can help:



A dedicated Patient Support Manager

A single point of contact who is ready to assist your loved one with product support needs



Financial assistance options

Co-pay assistance for those who are eligible,* as well as assistance with navigating insurance coverage



Injection training

In-home training from a specially trained nurse for you and your loved one on how to self-administer TAKHZYRO



Resources and education

Connecting you and your loved one with educational resources, including the free OnePath Mobile App

*At a minimum to be eligible, patients must have commercial insurance. Other terms and conditions apply. Contact OnePath for more information.



My OnePath Patient Support Manager is amazing. She checks in on me to see if I have any problems accessing my medication."

—Kelly

Real TAKHZYRO patient



You can also connect with other patients living with HAE.

Contact the Hereditary Angioedema Association (HAEA) by calling **1-866-798-5598**, or emailing [**mentors@haea.org**](mailto:mentors@haea.org) to learn more about the Patient Health Advocate Program.

REIMAGINE LIFE WITH HAE

Support for the next chapter



Take care of yourself every chance you get—caregiving is hard work



Accept offers of help and seek assistance if you need it. There are organizations for people with HAE and other rare diseases that can provide resources and support



Stay informed about HAE and treatment with TAKHZYRO. Sign up to receive the latest news at [TAKHZYRO.com](https://www.takeda.com/takhzyro)



Remind your loved one to take TAKHZYRO as prescribed and not to miss or skip doses

IMPORTANT SAFETY INFORMATION

TAKHZYRO may cause serious side effects, including allergic reactions. Call your healthcare provider or get emergency help right away if you have any of the following symptoms:

- wheezing
- chest tightness
- faintness
- hives
- difficulty breathing
- fast heartbeat
- rash

Please see additional Important Safety Information throughout and full [Prescribing Information](#), including information for patients.



©2021 Takeda Pharmaceutical Company Limited. 300 Shire Way. Lexington, MA 02421. 1-800-828-2088. All rights reserved. TAKEDA and the TAKEDA logo are trademarks or registered trademarks of Takeda Pharmaceutical Company Limited. TAKHZYRO is a registered trademark of Dyax Corp., a Takeda company. OnePath is a registered trademark of Shire, a Takeda company. US-LANA-0702v1.0 03/21

Visit us on:



youtube.com/takhzyro
facebook.com/takhzyro

TAKHZYRO[®]
(lanadelumab-flyo) injection



**Patient Support Manager
contact information**

NAME

PHONE NUMBER

EMAIL

US-LANA-0702v1.0 03/21

**Fill out and print these
cards for easy access to
the contact information
for your loved one's
Patient Support Manager.**



**Patient Support Manager
contact information**

NAME

PHONE NUMBER

EMAIL

US-LANA-0702v1.0 03/21